Jazz Disputes FDA’s Approval Of Lumryz Over Xywav’s Orphan Exclusivity, Citing Lack Of …

Jazz’s REMS patent on distribution of Xyrem does not belong in the Orange … Under the Orphan Drug Act, orphan drug exclusivity prevents FDA from …